Company profile
Merus N.V.
Pipeline5 assets
- PetosemtamabMCLA-158 / EGFR x LGR5 / Bispecific Antibody / Oncology1L PD-L1+ r/m head and neck squamous cell carcinoma (with pembrolizumab)Phase 3OngoingGlobal2/3L r/m head and neck squamous cell carcinomaPhase 3OngoingGlobal1L metastatic colorectal cancer (with standard chemotherapy)Phase 2OngoingGlobal
- ZenocutuzumabMCLA-128 / BIZENGRI / HER2 x HER3 / Bispecific Antibody / OncologyPancreatic adenocarcinoma (NRG1 fusion-positive)ApprovedApprovedUnited StatesNon-small cell lung cancer (NRG1 fusion-positive)ApprovedApprovedUnited StatesOther non-NRG1+ cancerPhase 2OngoingGlobal
- MCLA-129MCLA-129 / EGFR x c-MET / Bispecific Antibody / OncologySolid tumorsPhase 1/Phase 2OngoingGlobal2L+ EGFRm non-small cell lung cancer (with chemotherapy)Phase 2OngoingGlobal
- BesufetamigONO-4685 / PD-1 x CD3 / Bispecific Antibody / Oncology, ImmunologyRelapsed/Refractory T Cell LymphomaPhase 1OngoingGlobalPsoriasisPhase 1OngoingGlobal
- INCA33890INCA33890 / PD-1 x TGFBr2 / Bispecific Antibody / OncologySelect advanced solid tumorsPhase 1OngoingGlobal
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.